WHY IT MATTERS: Patients dealing with cancer-related cachexia, HIV-associated wasting, or medication-induced appetite suppression may have a clearer scientific basis for discussing cannabis-based appetite support with their physician. CLINICAL OVERVIEW: Cannabis has long been observed to stimulate appetite through its interaction with the endocannabinoid system, particularly via CB1 receptor activation in regions of the brain that regulate hunger and reward. This mechanism, commonly called “the munchies,” involves not just peripheral hunger signals but also a shift in how the brain perceives and prioritizes food-related cues.
Secondhand marijuana smoke has fine particles that can cause asthma attacks and … – Instagram
WHY IT MATTERS: If you or someone in your household has asthma or another respiratory condition, exposure to secondhand marijuana smoke in shared spaces like homes or vehicles can trigger serious symptoms even without directly using cannabis. CLINICAL OVERVIEW: Secondhand marijuana smoke contains fine particulate matter that can trigger respiratory inflammation and exacerbate conditions like asthma, making exposure a legitimate public health concern beyond the individual user. Unlike the common assumption that cannabis smoke is less harmful than tobacco smoke, the combustion process produces many of the same irritants and carcinogens regardless of the plant material being burned.
Medicare may soon cover certain cannabis medications for seniors – MSU Denver RED
WHY IT MATTERS: If Medicare begins covering cannabis-based medications, seniors who currently spend hundreds of dollars monthly out of pocket on cannabinoid therapies could see significant cost relief and improved access to physician-supervised treatment plans. CLINICAL OVERVIEW: The possibility of Medicare covering certain cannabis-based medications represents a significant shift in how the federal government treats cannabinoid therapeutics for older adults. From a clinical standpoint, this could dramatically improve access for seniors who currently pay entirely out of pocket for cannabis medicines, often on fixed incomes, while simultaneously catalyzing the rigorous research needed to establish evidence-based dosing protocols and safety profiles for this population.
Florida Lawmakers Vote To Slash Medical Marijuana Fees For Military Veterans
WHY IT MATTERS: If you are a military veteran in Florida seeking a medical marijuana card, this bill could meaningfully reduce your out-of-pocket registration costs and make it easier to start or maintain your cannabis treatment plan. CLINICAL OVERVIEW: Florida is advancing legislation to reduce the cost of medical marijuana registry identification cards for military veterans, addressing a longstanding financial barrier that has kept some veterans from accessing state-legal cannabis therapy. Veterans disproportionately suffer from chronic pain, PTSD, traumatic brain injury, and sleep disorders, all conditions where cannabis medicine has shown meaningful clinical benefit.
Rapid Dose Therapeutics Advances Cannabinoid Studies for QuickStrip Drug Delivery Platform
WHY IT MATTERS: If oral thin film cannabinoid delivery becomes clinically available, patients who struggle with inconsistent edible absorption or who cannot inhale may gain access to a faster-acting, more precisely dosed alternative. CLINICAL OVERVIEW: Oral thin film delivery systems for cannabinoids represent an evolving area of drug delivery research that could address some of the longstanding challenges in cannabis medicine, including inconsistent absorption, delayed onset, and difficulty achieving precise dosing. From a clinical perspective, sublingual and buccal delivery methods bypass first-pass hepatic metabolism, potentially offering more predictable pharmacokinetics compared to traditional edibles while providing a smoke-free alternative for patients who need rapid onset without inhalation.
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
WHY IT MATTERS: If you or a loved one is living with Alzheimer’s-related agitation, the expansion of this clinical trial means more opportunities to access investigational cannabinoid therapy and brings us closer to having FDA-reviewed evidence for cannabis-based treatment options in dementia care. CLINICAL OVERVIEW: The expansion of clinical trial sites for IGC Pharma’s Phase 2 CALMA trial investigating cannabinoid-based therapy for Alzheimer’s-associated agitation represents a meaningful step in building the evidence base for cannabis medicine in neurodegenerative disease. Alzheimer’s-related behavioral symptoms like agitation and aggression are notoriously difficult to manage with conventional medications, and cannabinoid therapies have shown early promise in addressing neuroinflammation and behavioral dysregulation through endocannabinoid system modulation.
DOJ Suggests ‘Frail and Elderly Grandmother’ Who Uses Medical Marijuana Could Face Armed Federal Agents
Ohio’s ability to identify and recall unsafe THC gummies proves that legal, regulated markets protect consumers in ways that unregulated black markets never can. Marijuana Moment reports on a DOJ filing suggesting that even a ‘frail and elderly grandmother’ who uses medical marijuana could theoretically face enforcement by armed federal agents under current law. The argument arose in litigation over the intersection of cannabis use and firearms rights under the Second Amendment.
Study Challenges Negative Cannabis Stereotypes, Claiming Link to Brain Benefits
Researchers confirmed that cannabis universally increases appetite regardless of your body type, gender, or how recently you ate—knowledge that could help develop better treatments for patients who can’t eat due to illness. Researchers at the University of Colorado Anschutz Medical Campus analyzed cannabis usage, brain scans, and cognitive test results for over 26,000 adults ages 40-77 using UK Biobank data. Moderate lifetime cannabis users showed larger volumes in brain regions rich in CB1 receptors—areas involved in memory, information processing, and emotion regulation.